Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study.
Adrenal metastases
Oligometastatic
Oligoprogression
Radiotherapy
Stereotactic body radiation therapy
Journal
Cancer treatment and research communications
ISSN: 2468-2942
Titre abrégé: Cancer Treat Res Commun
Pays: England
ID NLM: 101694651
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
09
2021
revised:
06
10
2021
accepted:
19
10
2021
pubmed:
27
10
2021
medline:
11
3
2022
entrez:
26
10
2021
Statut:
ppublish
Résumé
To evaluate survival outcomes and toxicology profiles in oligometastatic/oligoprogressive patients treated with SBRT for adrenal metastases. We retrospectively analyzed 25 metastatic adrenal lesions in 24 oligometastatic/oligoprogressive patients undergoing ablative Stereotactic Body Radiation Therapy (SBRT) between February 2010 and November 2019 in our department. The primary endpoint was overall survival (OS). Secondary endpoints were local overall response rate (ORR), acute and late toxicities. The most common primary tumor was non-small cell lung cancer (54%). Twenty-one patients received chemo or immuno-therapy. The median planning target volume (PTV) was 41.7 cm SBRT for oligometastatic/oligoprogressive patients with adrenal metastases showed acceptable survival outcomes and a safe toxicity profile.
Identifiants
pubmed: 34700142
pii: S2468-2942(21)00177-5
doi: 10.1016/j.ctarc.2021.100481
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100481Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.